News & Insights

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company’s clinical candidates and extern

LOS ANGELES--(BUSINESS WIRE)--AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded version produced by ViiV Healthcare. “Colombia is fully within its rights to issue a compulsory license by exercising the flexibilities under the World Trade Organization rules in the interest of public health of its citize

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales grew 8% adjusted for billing days Q1 TMTT sales grew 75% Q1 EPS of $0.58; adjusted1 EPS of $0.66 Raising 2024 sales guidance to the high end of previous 8 to 10%1 range Raising full-year 2024 sales guidance for TMTT

CLAREMONT, Calif.--(BUSINESS WIRE)--Synedgen Completes IND-Enabling Studies for Two Parallel Programs for Lead Asset MIIST305

HAWTHORNE, Calif.--(BUSINESS WIRE)--OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced its financial results for the three and nine months ended March 31, 2024. Deepak Chopra, OSI Systems’ Chairman and Chief Executive Officer, stated, “We are pleased to report strong financial results as outstanding performance in the Security division led to record third quarter revenues and adjusted earnings per share. Given continued solid bookings, a strong backlog, and high v

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab) and standard-of-care chemotherapy to be discussed during the upcoming conference call. The results continue to reinforce ImmunityBio’s belief in the unique mechanism of action of ANKTIVA (N-803, o

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (“Sonendo”) (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the first quarter 2024 after the market close on Wednesday, May 8th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results. Investors interested in listening to the conference call may do so by diali

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at https://ir.arrowheadpharma.com/events-and-presentations. A replay of the webcast will be available approximately two hours aft

LOS ANGELES--(BUSINESS WIRE)-- #Biotech--Molecular Instruments announced that the Patents Court of England and Wales found two patents owned by Advanced Cell Diagnostics to be invalid.

AGOURA HILLS, Calif.--(BUSINESS WIRE)-- #A2Bio--A2 Bio to Highlight Progress of CAR T Clinical Programs in Three Poster Presentations at 2024 ASCO Annual Meeting

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May 7, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks. To parti

LOS ANGELES--(BUSINESS WIRE)-- #binary--Binarly, provider of an industry leading AI-powered firmware and software supply chain security platform, announces the release of the Binarly Transparency Platform v2.0 with features for continuous post-build compliance, visibility into the security posture of IoT and XIoT devices, and the ability to identify malicious behavior and hidden backdoors within binaries based on their behavior. Learn more here. Based on the company’s proprietary Binary Risk Intelligence

BOSTON & NASHVILLE, Tenn. & ORANGE, Calif. & ATLANTA--(BUSINESS WIRE)--An automated tool that improves outbreak detection for hundreds of pathogens successfully served as an early warning system to find and respond to potential hospital outbreaks, as reported today in NEJM Evidence. A Trial of Automated Outbreak Detection to Reduce Hospital Pathogen Spread The large multi-state, real-world study was conducted in 82 hospitals and led by Harvard Pilgrim Health Care Institute, HCA Healthcare, Univ

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release first quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, May 7, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. “The FDA’s approval of ANKTIVA marks our launch of a next-generation immun

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue it's 1Q-2024 results after the close on May 2, 2024, and host a conference call to discuss results at 1:30 p.m. PDT.

IRVINE, Calif.--(BUSINESS WIRE)-- #AAA2024--New research presented at AAA uncovered significant improvements in QoL measures with smartphone calls when using the InnoCaption captioning app.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards L

HAWTHORNE, Calif.--(BUSINESS WIRE)--OSI Systems, Inc. (Nasdaq: OSIS) today announced that it will hold its quarterly conference call on Thursday, April 25, 2024 at 9:00am PT to discuss its results for the quarter ended March 31, 2024. This call is being webcast through the investor relations section at www.osi-systems.com. A replay of the conference call will be available from 12:00pm PT on April 25, 2024 until May 9, 2024. The replay may be accessed by visiting the investor relations section a

LOS ANGELES--(BUSINESS WIRE)--Measles is Back Thanks to Vaccination Backlash, Notes AHF

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Report can be found on the company’s website here. “I am prou

SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The following statement can be attributed to Joe Panetta, Biocom California’s president and CEO, and Kendalle Burlin O’Connell, Massachusetts Biotechnology Council’s (MassBio) CEO and president. “We strongly support efforts to continue American leadership in the biotechnology sector. We must look at ways to expand domestic capabilities for pharmaceutical research and manufacturing to ensure patient access

LONG BEACH, Calif.--(BUSINESS WIRE)--Ark Clinical Research Announces Advancing Accessibility for Obesity Through Innovative Research Trials on GLP-1 Drugs

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode announces the launch of the BioCode® STI + Resistance Panel (RUO).

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 9,651 shares of Evolus and an aggregate of 20,971 restricted stock units (RSUs) of the company’s common stock to 10 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of

LOS ANGELES--(BUSINESS WIRE)-- #Africa--AIDS Healthcare Foundation (AHF) says Moderna’s promise to build a state-of-the-art mRNA manufacturing facility in Africa in 2022 was nothing more than a self-serving effort to deflect criticism for price gouging on its COVID-19 vaccine after the pharma company announced today that it’s suspending the project. “Moderna’s greed knows no bounds. It raked in $30 billion in profit since 2021. Now, it claims the mRNA factory in Kenya is no longer worth the investment be

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer question

LOS ANGELES--(BUSINESS WIRE)--The Milken Institute today announced its program agenda and initial list of distinguished speakers for its 2024 Global Conference, taking place from May 5 – 8 at The Beverly Hilton in Los Angeles, CA. Centered around the uniting theme of “Shaping a Shared Future,” the four-day event will convene influential leaders from around the world to discuss, explore and catalyze ideas to guide solutions to many of today’s global issues. With more than 150 conversations and p

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia®, Inc. announced today that the company’s 80-gene molecular subtyping assay, BluePrint®, is now included in the latest version of German Gynecological Oncology Group (AGO) guidelines. The assay was added to the list of predictive factors for neoadjuvant chemotherapy decision making. Agendia’s MammaPrint® was added to the AGO guidelines in 2017, with level 1B medical evidence for identification of patient subgroups who can potentially forgo ch

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 financial results after the market close on Wednesday, May 1, 2024. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on May 1, 2024. A link to the live

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance

LOS ANGELES--(BUSINESS WIRE)--Researchers with City of Hope®, one of the largest cancer research and treatment organizations in the United States, will present more than 70 abstracts and sessions on innovative clinical trial results, breakthrough diagnostic techniques and advances in treatment options as well as share their expertise on molecular profiling and the microbiome at the AACR Annual Meeting, which started April 5 and ends April 10 in San Diego. In addition to City of Hope’s robust da

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device. The clinical trial—Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Clinical Study— began in May 2022. SCONE is an innovative device that treats urinary incontinence allowing people living with neurogenic bladder due to spinal cord injury, multiple sclerosis, or stroke to live life on their own terms. SpineX scientists and resea

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG). Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels. These data were prese

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- #digitalhealth--egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 ACC Conference

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara

IRVINE, Calif.--(BUSINESS WIRE)--Cloudbreak Pharma, a clinical stage biotechnology company developing ophthalmic drugs for common eye diseases with few treatment options, shared new data from a company-supported survey highlighting the patient burden of pterygium at the annual ASCRS meeting in Boston. Pterygium is an ocular disease commonly referred to as “surfer’s eye,” which can result from exposure to high levels of UV radiation.1 The cross-sectional survey revealed 50 percent of respondents

IRVINE, Calif.--(BUSINESS WIRE)-- #ClinicalTrials--Immunis Inc., a leading biotech in secretome therapeutics addressing age-related diseases and immune dysfunction, is proud to unveil its latest video project entitled “Unlocking Lifelong Vitality: Immunis Aims to Supercharge Our Immune System for a Healthier Future.” This project features insights from world-renowned leaders in human health including Dr. Hans Keirstead, Jane Metcalfe, Dr. Peter Diamandis and Dr. Micah Drummond, who share a vision of revolutioniz

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the US FDA has again renewed licenses to its DILIsym QST software to support informed decision-making in drug approvals.

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter. This represents the Company’s highest quarterly ICL sales in the U.S. since the Compa

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported an inducement award granted to one new hire in March 2024, as required under Nasdaq Listing Rule 5635(c)(4).

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for iDose® TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reductio

HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--Leonid Capital Partners, an investment firm focused on high-growth tech companies in the national security industry, named Ian L. Holroyd as its CFO.

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, comes to the American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in Boston from April 5-8, 2024, fresh off the achievement of a new commercial milestone: three million lenses sold. Furthering the momentum behind its flagship product, EVO ICL, the compa

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 30, 2024, the Company’s Board of Directors approved “inducement” grants to 32 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 31,700 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and vest

SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today released its 2023 Impact Report. The full FIGS 2023 Impact Report is available at wearfigs.com/impactreport and provides a comprehensive view into FIGS’ efforts to positively impact healthcare professionals. “Since day one, FIGS has been on a mission to improve the lives of healthcare workers globally,” said Trina Spear,

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today confirmed that Politan Capital Management LP (“Politan”) has provided notice of its intent to nominate two candidates to stand for election to the Masimo Board of Directors at the company’s 2024 Annual Meeting. While Masimo respects and values the input and ideas of all its stockholders and respects their right to nominate and elect the directors of their choice, the Company believes that Politan’s efforts to take control of the Board

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA. Glaukos will be exhibiting onsite at booth #631. In addition, Glaukos is spon

GLENDALE, Calif.--(BUSINESS WIRE)--Ventegra, Inc., a Medical Benefit Manager (MBM) that delivers innovative, cost-efficient pharmaceutical and healthcare solutions to payors, providers, and patients, today announced the launch of the Ventegra Access Program (VAP). The program underscores Ventegra’s deep understanding of the value of the coordinated care delivery model and serves the needs of those with similar goals and objectives. Brian Vossler, Vice President, Business Development, says, “The

LOS ANGELES--(BUSINESS WIRE)--Aspect Imaging, the leading provider of compact MRI solutions, is proud to announce the successful installation of the Embrace® Neonatal MRI System at The Hospital for Sick Children (SickKids) in Toronto, Ontario, marking a significant milestone as the first installation of its kind in Canada. The Embrace® Neonatal MRI System, renowned for its compact design and advanced patient-focused approach to MRI, is specifically tailored to meet the unique needs of premature